Anavex Life Sciences Corp.
AVXLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAnavex Life Sciences Corp. operates as a biopharmaceutical company. The $236.8M market capitalization puts AVXL squarely in micro-cap range for its industry. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer.
Market Cap
$236.8M
Beta
1.14
P/E (TTM)
—
P/E (Fwd)
-4.65
EPS (TTM)
$-0.48
EPS (Fwd)
$-0.55
ROE
-33.6%
ROA
-21.6%
Cash
$131.7M
Total Debt
$0
Free CF
-$21.8M
52W Change
-77.1%
Annual Financials
Cash vs Debt
Where AVXL stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, AVXL finished 32.69% below its 150-day moving average ($3.61) and 45.88% below its 200-day moving average ($4.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVXL overbought or oversold?
At the July 15, 2026 close, AVXL's RSI(14) was 43.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Anavex Life Sciences Corp. reports $131.7M in cash and $0 in total debt. Free cash flow is running at -$21.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -33.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AVXL.